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Abstract 
Background: To assess the conclusiveness of Cochrane Eye and Vision Group Reviews (EVGRs). We tested the 
hypotheses that: (1) the majority of EVGRs are inconclusive; (2) most reviews state the need for further and better 
studies; (3) the conclusiveness of a given review is affected by the number of randomized controlled trials (RCTs) 
included and the cumulative number of patients and eyes studied.
Methods: A retrospective study of all EVGRs available in the Cochrane Library in June 2013. For each EVGR we 
recorded the number of RCTs found by the reviewers, the number of RCTs included for final analysis as fulfilling inclu-
sion criteria, the total cumulative number of patients and eyes studied, the stated need for further and better studies, 
the reason stated for further studies and the type of conclusion reached by the reviewer(s). We used the Kruskal–Wal-
lis test to determine differences between ‘‘conclusive’’ and ‘‘inconclusive’’ studies in terms of the outcome variables 
studied. The correlation between the number of included studies and cumulative sample size was studied using 
regression analysis.
Results: Out of 106 EVGRs, 52.8% were conclusive. In 83.9% of the conclusive EVGRs one treatment/strategy/drug 
was found to be better than the alternative. The average number of available and included RCTs was significantly 
higher in conclusive EVGRs (P = 0.007 and P = 0.003 respectively). The total cumulative number of patients and num-
ber of eyes studied was approximately ten times higher in the conclusive EVGRs (P < 0.001 and P < 0.015 respectively). 
A similar percentage of RCTs was included in both conclusive and inconclusive reviews (76 vs. 73%). The vast majority 
of EVGRs, whether conclusive (84%) or inconclusive (96%), stated the need for further and better studies (P = 0.042). 
Fifty eight percent of the EVGRs justified the need for further studies for at least two reasons. The reason that was 
stated the most was a need for a larger amount of RCTs (67%).
Conclusions: In approximately half of the cases, EVGRs allow the reader to reach a clinically applicable conclusion. 
Larger total cumulative participants, total cumulative number of eyes studied and number of RCTs performed all 
increase the likelihood of an EVGR to be conclusive.
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Background
In 1993, the Cochrane collaboration was founded in 
response to Archie Cochrane’s call for systematic reviews 
of randomized controlled trials (RCTs) in healthcare [1]. 
The collaboration is now a huge network of more than 
28,000 volunteer contributors from over 100 countries [1].
The Cochrane collaboration has been noted by Grim-
shaw to be “the best single resource for methodologic 
research and for developing the science of meta epidemi-
ology” [2]. The ultimate goal of the Cochrane reviews is 
to organize medical research information in a systematic 
way that allows end-users to reach practical conclusions 
in the interests of evidence based medicine [1].
It has been suggested that the goals of the Cochrane 
reviews are not always reached: indeed, not all Cochrane 
reviews are conclusive and even when they are it is often 
stated that there is a need for more and better studies 
[3–5]. Based on previous reports, 64–80% of Cochrane 
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reviews are conclusive. However, a majority emphasizes 
the need for further studies [3–5]. Therefore, approxi-
mately one out of three times the reader is not able to 
reach a clinically applicable conclusion. To the best of 
our knowledge, no previous studies have reported on 
the conclusiveness of Cochrane reviews in the field of 
Ophthalmology.
We therefore designed the current study of all 106 
Cochrane Eye and Vision Group Reviews (EVGRs) avail-
able until June 1 2013. We aimed to assess the conclusive-
ness of the EVGRs.
Similar to previous definitions we characterized con-
clusiveness by the ability or not to reach a practical 
definitive conclusion stating that one treatment was sig-
nificantly better or not than another treatment or placebo 
[3–5]. Based upon our own previous experience\personal 
bias we hypothesized that: (1) the majority of the EVGRs 
are inconclusive; (2) most reviews state the need for fur-
ther and better studies; (3) the conclusiveness of a given 
review is affected by the number of RCTs included in the 
review and the cumulative number of patients retained 
for analysis.
Methods
We selected all of the 106 EVGRs available in the 
Cochrane Library on 1 June 2013 [6]. Two authors (MM 
and FM) independently extracted the following charac-
teristics from each review: number of RCTs found by the 
reviewers on the topic, number of RCTs included for final 
analysis as fulfilling the criteria for inclusion, total cumu-
lative number of patients enrolled in the included studies, 
total cumulative number of eyes studied (whenever avail-
able), stated need or not for further and better studies, 
reason stated for further studies and type of conclusion 
reached by the reviewers. A third reviewer was available 
if disagreement arose (FS). Many EVGRs report both the 
number of individuals recruited and the number of eyes 
studied and therefore the same principle was applied in 
this study. The reason stated for further study was pro-
spectively classified into 7 subcategories: (1) need for fur-
ther and better studies in a subgroup of patients in the 
review; (2) too small of a sample size in existing RCTs; (3) 
too small of a RCT number; (4) need for further studies 
to detect potential side effects; (5) need for further stud-
ies to determine long term outcomes; (6) need for further 
studies comparing multiple or new strategies; (7) other 
reasons.
The type of conclusion reached by the reviewers was 
classified into five subcategories: (1) the treatment/
strategy/drug was found to be better than the alterna-
tive (other treatment/strategy/drug or placebo); (2) no 
significant differences were found between the two treat-
ments/strategies/drugs; (3) no decision could be reached 
because the existing RCTs were of poor quality; (4) no 
decision could be reached because of not enough data; 
(5) no decision could be reached because of outdated 
existing RCTs. The first two categories of reviews were 
defined by us as ‘‘conclusive’’, and the last three as ‘‘incon-
clusive’’. For the purpose of determining conclusiveness, 
only the main outcome was considered.
Minitab version 16.1 (State College, PA, USA) was 
used for statistical analyses. We used the Kruskal–Wal-
lis test to determine differences between ‘‘conclusive’’ and 
‘‘inconclusive’’ studies in terms of the outcome variables 
studied. The correlation between the number of included 
studies and cumulative sample size was studied using 
regression analysis. Results are expressed as mean ± SD, 
median (range) or number (%). A P value of <0.05 was 
considered to be statistically significant.
Results
We identified 106 EVGRs. The range, median, and mean 
number of RCTs examined, number of RCTs included for 
analysis, total cumulative number of patients enrolled, 
total cumulative number of eyes studied, the stated need 
or not for further and better studies and type of conclu-
sion reached by the reviewers are described in Table  1. 
Briefly 56 (52.8%) EVGRs fulfilled our criteria for being 
conclusive versus 50 inconclusive (47.2%). Among the 
‘‘conclusive’’ reviews, in 47 of them (83.9%) one treat-
ment/strategy/drug was found to be better than the 
alternative and in 9 of them (16.1%) no significant differ-
ences were found between the two treatments/strategies/
drugs. Among the EVGRs classified as ‘‘inconclusive’’ 
5 (10%) were judged so because the RCTs were of poor 
quality, 44 (88%) because there were not enough data, 
and 1 (2%) because the RCTs were found to be outdated. 
The average number of available RCTs was significantly 
higher in conclusive EVGRs than in inconclusive ones 
(P = 0.007). The average number of included RCTs was 
significantly higher in conclusive reviews than in incon-
clusive ones (P = 0.003). Also, the total cumulative num-
ber of patients enrolled was more than ten times higher 
in the conclusive EVGRs than in the inconclusive ones 
(P < 0.001). In addition, the total cumulative number of 
eyes studied was nearly ten times higher in the conclusive 
EVGRs than in the inconclusive ones (P < 0.015). A simi-
lar percentage of RCTs was included in both conclusive 
and inconclusive reviews (76 vs. 73%). The vast major-
ity of EVGRs, whether conclusive (84%) or inconclusive 
(96%), stated the need for further and better studies with 
the percentage being significantly higher in the inconclu-
sive group (P = 0.042). The EVGRs justified the need for 
further studies as follows: 34% required further studies in 
subgroups, 17% required studies with larger sample sizes, 
67% required a larger amount of studies, 12% required 
Page 3 of 4Mimouni et al. BMC Res Notes  (2015) 8:242 
further studying of side effects, 29% needed monitoring 
of long term outcomes and 33% required further studies 
because of multiple or new strategies\drugs\therapies. 
Obviously, many of the reviews (58%), justified the need 
for further studies for at least two reasons.
In a few of the reviews it was impossible to retrieve 
either the number of total cumulative participants (5%) 
and in many reviews it was impossible to retrieve the 
total cumulative number of eyes studied (42%) as they 
were not stated by the reviewers.
Discussion
Contrary to our hypothesis, a very small majority of 
EVGRs was conclusive. In fact, 52.8% of EVGRs fulfilled 
our criteria for being conclusive. Thus, a researcher or 
clinician who wants a definite answer on a specific issue 
raised and summarized by the Cochrane Eye and Vision 
Group will get this answer approximately half of the time.
In the vast majority (83.9%) of the conclusive reviews 
one treatment\strategy or drug was found to be better 
than the alternative or placebo and only in 16.1% of con-
clusive reviews no significant differences were found. This 
point, is probably related to the fact that when a signifi-
cant difference is found there is an intuitive conclusion 
that the answer is definitive, while when no differences 
are found (when the null hypothesis cannot be rejected) 
there is still a remaining issue of potentially insufficient 
power (that might still be improved by increasing the 
sample size). An alternative explanation could be pub-
lication bias. Indeed, articles with positive results are 
more likely to be published than those reporting nega-
tive results [7, 8]. They are also more likely to be accepted 
for publication in a journal of greater impact factor [9]. 
Thus, the total sample size of studies reporting positive 
results is likely to be larger than the total sample size of 
those reporting negative results. Indeed, from our study, 
it appears that the total number of available RCTs as well 
as the total number of retained RCTs, and subsequently 
the total number of participants and the total number 
of eyes studied were much higher in conclusive EVGRs 
than in inconclusive ones. The association between sam-
ple size and conclusiveness was also observed in previous 
reports in other fields of medicine [3, 4]. Interestingly, the 
percentage of RCTs included in the final analysis from all 
available RCTs was nearly identical between conclusive 
and inconclusive EVGRs. We speculate, that the stringent 
and systematic approach of the Cochrane Eye and Vision 
Group for including or excluding RCTs explains the con-
sistency of exclusion percentages.
There was a stated need for further and better studies 
in 84% of conclusive EVGRs and in 96% of inconclusive 
ones. Although, the difference between 96 and 84% was 
statistically significant (P = 0.042), it is still apparent that 
in both groups the vast majority of EVGRs stated such a 
need. Fifty eight percent of the EVGRs justified the need 
for further studies for at least two reasons but the reason 
that was stated the most was a need for a larger amount 
of studies (67%). The second most frequently stated rea-
son was the need for further studies in subgroups (34%), 
while the third most frequently stated reason was the 
need for further studies because of multiple or new strat-
egies\drugs\therapies (33%). Thus, it appears that in most 
cases whether or not current science supports one type 
of evidence, the Cochrane Eye and Vision Group often 
concludes that there is room for more evidence, although 
there are limited resources for research.
It is worth noting that three of our previous reports 
of the conclusiveness of Cochrane reviews in neonatol-
ogy [3], pediatric-gastroenterology [4] and nutrition [5] 
demonstrated higher rates of conclusive reviews (67.7, 
80 and 64.4% respectively) when compared to that of 
the EVGRs. On one hand, this perhaps provides us with 
a state of play on how much of the ophthalmic practice 
is well supported by high-level evidence when compared 
to the previously mentioned fields despite the upward 
growing trend of overall publications in the field of 
ophthalmology [10]. On the other hand this may be the 
result of the Eye and Vision Group dealing with novel 
Table 1 Study characteristics of the Cochrane Eye and Vision Group Reviews (EVGRs)
RCTs randomized controlled trials, EVGRs Eye and Vision Group Reviews.
a Mean ± SD.
b Median (range).
c In 101 of the EVGRs the total cumulative number of participants could be retrieved, 52 of them were conclusive reviews and 49 of them were inconclusive ones.
d In 62 of the EVGRs the total cumulative number of eyes studies could be retrieved, 26 of them were conclusive reviews and 36 were inconclusive ones.
‘‘Conclusive’’ EVGRs (n = 56) ‘‘Inconclusive’’ EVGRs (n = 50) P
Number of RCTsa 10.7 ± 17.1 3.22 ± 5.57 0.003
Total cumulative number of patients enrolledb,c 984 (439–117,272) 50 (0–12,294) <0.001
Total cumulative number of eyes studieda,d 1,295 ± 2,240 136.2 ± 287.9 0.015
Percent of EVGRs where further studies are neededa 96 ± 20 84 ± 37 0.042
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and “problematic” clinical questions which have yet to be 
investigated sufficiently.
A limitation of the EVGRs was that it was not always 
possible to retrieve either the number of total cumula-
tive participants or the total cumulative number of eyes 
studied as they were not stated by the reviewers. We sug-
gest that there is room for improvement in the report-
ing of RCTs which should all clearly state both numbers. 
Another limitation of the study is that other characteris-
tics of EVGRs such as the types of comparisons included 
and how broad or narrow the questions are were not 
collected and analyzed. In addition, the field of Oph-
thalmology is so highly specialized and therefore, retina 
specialists, for instance, may have better success with 
using EVGRs to answer clinical questions as opposed 
to neuro-ophthalmologists or glaucoma specialists. An 
additional limitation of this study is that though it does 
not provide insight regarding the quality of the EVGRs 
or their usefulness. An inconclusive review may be of 
very good quality and be thorough, of great help to the 
end-user (summarizing evidence from many sources 
into one article), and pertinently identifying gaps in our 
understanding and priorities for future research. In fact, 
an inconclusive review may be more useful than a con-
clusive one. Finally, the primary purpose of Cochrane 
reviews is really to establish a level of evidence by per-
forming a systematic review of the literature. Its primary 
purpose might not be to “render decisions” regarding 
whether a treatment is better or not, and in fact it may 
appear that Cochrane review groups discourage authors 
from being prescriptive in their discussion and conclu-
sions. In addition, Cochrane reviews provide informa-
tion on other aspects of treatment such as side-effects 
encountered but the scope of our study was to review the 
primary outcomes of the reviews.
Conclusions
In summary, we found that the EVGRs allow, in approxi-
mately half of the cases, the reader to reach a clinically 
applicable conclusion. The Cochrane Eye and Vision 
Group, in a large majority of the reviews, emphasize the 
weaknesses of both conclusive and inconclusive reviews 
and suggest avenues for future and better research. The 
percentage of conclusive Cochrane reviews is lower in 
ophthalmology than in other fields of medicine studied in 
a similar fashion.
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